首頁/股票/ZYME

ZYME

USD

Zymeworks Inc. Common Stock

$18.160-0.230 (-1.251%)

即時價格

Healthcare

生物科技

美國

價格圖表

Loading Chart...

關鍵指標

市場指標

公司基本面

交易統計

市場指標

開盤

$18.390

最高

$18.770

最低

$18.000

交易量

0.08M

公司基本面

市值

1.4B

行業

生物科技

國家

United States

交易統計

平均交易量

0.66M

交易所

NMS

貨幣

USD

52週範圍

最低 $9.03當前 $18.160最高 $19.98

相關新聞

2025年10月28日 · 上午10:00

GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

Zymeworks Announces Participation in Upcoming Investor Conferences

2025年10月23日 · 下午04:30

GlobeNewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

2025年10月14日 · 上午11:15

Analyst Upgrades

HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.

HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26

2025年10月13日 · 下午08:00

GlobeNewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

2025年10月10日 · 下午01:28

Analyst Upgrades

B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.

B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30

GlobeNewswire

2025年10月9日 · 上午10:00

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the